Corrigendum to ‘Targeting FGFR2 With Alofanib (RPT835) Shows Potent Activity in Tumour Models’ [Eur J Cancer 61 (2016) 20–28]
European Journal of Cancer - United Kingdom
doi 10.1016/j.ejca.2016.11.001
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2017
Authors
Publisher
Elsevier BV